tiprankstipranks
Trending News
More News >
Advertisement

MFDX - ETF AI Analysis

Compare

Top Page

MFDX

PIMCO RAFI Dynamic Multi-Factor International Equity ETF (MFDX)

Rating:65Neutral
Price Target:
MFDX, the PIMCO RAFI Dynamic Multi-Factor International Equity ETF, earns a solid overall rating thanks to strong core holdings like Novartis and HSBC, which bring robust profitability, healthy balance sheets, and supportive technical trends to the portfolio. Additional positions in GlaxoSmithKline, Roche, and Nestlé further reinforce quality through solid cash flow and strategic growth initiatives, though some names such as Unilever and Iberdrola introduce concerns around valuation, market momentum, and higher debt. The main risk is the fund’s concentration in a relatively small group of large non-U.S. companies and sectors like pharmaceuticals and financials, which can make performance more sensitive to developments in those areas.
Positive Factors
Broad International Diversification
The fund spreads its investments across many countries, with meaningful exposure to Japan, the UK, Europe, and other regions, which helps reduce reliance on any single market.
Balanced Sector Mix
Holdings are spread across financials, industrials, consumer stocks, health care, and other sectors, which can help smooth out performance when one industry is struggling.
Generally Positive Recent Performance
The ETF has shown steady gains over the past month, three months, and year to date, indicating that its strategy has been working in the current market environment.
Negative Factors
Moderate Expense Ratio
The fund’s fee is not especially low for an ETF, which means a small but ongoing drag on returns compared with cheaper index funds.
Small Individual Position Sizes
Each top holding makes up less than 1% of the fund, so even strong performers like BAE Systems have only a limited impact on overall returns.
Mixed Performance Among Top Holdings
While several leading positions such as Novartis, Roche, HSBC, and BAE Systems have been strong, others like Nestlé and GSK have been weak, which can offset some of the gains.

MFDX vs. SPDR S&P 500 ETF (SPY)

MFDX Summary

MFDX is an international stock ETF that follows the RAFI Dynamic Multi-Factor Developed Ex-U.S. Index, focusing on companies outside the United States. It owns a wide mix of businesses across many countries like Japan, the UK, and Europe, and across many sectors such as financials, industrials, and healthcare. Well-known holdings include Nestlé, Novartis, and HSBC. Investors might consider MFDX to diversify beyond U.S. stocks and seek long-term growth from global markets. A key risk is that international stock prices can be volatile and can go up or down with global market and currency swings.
How much will it cost me?The PIMCO RAFI Dynamic Multi-Factor International Equity ETF (MFDX) has an expense ratio of 0.39%, which means you’ll pay $3.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it uses an actively managed multi-factor strategy to adjust its portfolio dynamically, aiming to optimize performance and reduce risk.
What would affect this ETF?MFDX’s focus on developed international markets and multi-factor investing could benefit from global economic growth, particularly in sectors like Financials and Industrials, which are heavily weighted in the fund. However, challenges such as rising interest rates, geopolitical tensions, or regulatory changes in key regions could negatively impact its performance, especially for top holdings like banks or consumer-focused companies. Diversification across sectors and countries helps mitigate risks but does not eliminate them entirely.

MFDX Top 10 Holdings

MFDX leans heavily on big European names, with banks and healthcare setting the tone. Rising financials like Banco Santander, Societe Generale, and HSBC are giving the fund a helpful tailwind, while defense contractor BAE Systems has been a standout, powering ahead in recent months. On the flip side, consumer staples giant Nestlé has been losing steam, and GlaxoSmithKline has shown more mixed progress, keeping overall gains in check. With broad developed-markets exposure outside the U.S., the fund is diversified by country but still tilts toward financials and defensive blue chips.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Novartis AG0.91%$4.06MCHF238.17B30.71%
80
Outperform
British American Tobacco0.89%$3.97M£94.42B43.93%
71
Outperform
Banco Santander0.86%$3.82M€147.24B79.52%
73
Outperform
Roche Holding AG0.83%$3.70MCHF287.83B46.49%
73
Outperform
GlaxoSmithKline0.81%$3.62M£87.35B52.52%
77
Outperform
Societe Generale0.74%$3.30M€44.19B78.66%
72
Outperform
Unilever0.64%$2.87M£118.46B10.24%
72
Outperform
Iberdrola0.64%$2.83M€133.99B48.26%
67
Neutral
Nestlé SA0.64%$2.83MCHF201.28B12.20%
71
Outperform
HSBC Holdings0.62%$2.76M£212.73B40.54%
80
Outperform

MFDX Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
39.62
Positive
100DMA
38.38
Positive
200DMA
36.80
Positive
Market Momentum
MACD
0.82
Negative
RSI
68.80
Neutral
STOCH
81.47
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MFDX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 41.04, equal to the 50-day MA of 39.62, and equal to the 200-day MA of 36.80, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 68.80 is Neutral, neither overbought nor oversold. The STOCH value of 81.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MFDX.

MFDX Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$445.62M0.39%
$965.76M0.50%
$681.69M0.29%
$649.49M0.39%
$582.45M0.59%
$446.25M0.23%
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MFDX
PIMCO RAFI Dynamic Multi-Factor International Equity ETF
42.39
11.17
35.78%
SEIE
SEI Select International Equity ETF
IDHQ
Invesco S&P International Developed High Quality ETF
TLTD
FlexShares Morningstar Developed Markets ex-US Factor Tilt
FYLD
Cambria Foreign Shareholder Yield ETF
AVSD
Avantis Responsible International Equity ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement